Novartis AG Weekly Chart
While sales grew last quarter, profitability was squeezed. Q2 core operating income was flat, and net income dropped 19% due to lower gross profits and higher tax and interest expenses. Investors will be looking for signs of margin stabilization in Q3 and whether the company is still on track for its full-year guidance of low single-digit core operating income declines.
Novartis ended Q2 with a sharply higher net debt of $39.4 billion following a $15.3 billion summer shopping spree. Markets will be listening closely to management's commentary on the integration of its July acquisitions and how they are accelerating the oncology and immunology pipelines.
Full-Year Guidance Check
Management reaffirmed its 2026 outlook at the end of Q2. With foreign exchange expected to provide a 1% tailwind, Q3 results will be the ultimate proving ground for whether Novartis can confidently lock in those full-year targets.
iShares MSCI Europe Health Care Sector UCITS ETF Chart
Year-to-date in 2026, Novartis AG has delivered more than 15.5% return, climbing from a starting price near 105.000 to its current level of 127.500. In comparison, the iShares MSCI Europe Health Care Sector UCITS ETF has gained roughly 6.4%, growing from an initial 2026 price of approximately 8.050 to 8.565. This demonstrates that Novartis has grown at more than triple the rate of the broader European healthcare ETF over the same period.
While the probability of capturing significant near-term upside in the fourth quarter remains constrained for both the individual equity and the broader ETF, there is a strong probability of a Q1 2027 resurgence. As portfolio managers recalibrate their strategic allocations for the new year, we are likely to see an elevated demand for the stability and reliable growth of defensive sector instruments like healthcare.